<DOC>
	<DOCNO>NCT00970996</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose Abraxane ( nab-paclitaxel ) give combination cisplatin , Temodar ( temozolomide ) , interferon alfa-2b , interleukin-2 ( IL-2 ) patient metastatic melanoma . Primary Objective : - The primary objective Phase I determine toxicity , safety maximum tolerate dose maximum tolerate dose Abraxane combination Cisplatin , Temozolomide , interleukin-2 interferon a2b patient metastatic melanoma . Secondary Objectives : - To assess response combination . - To evaluate duration response overall survival . - To determine effectiveness delay appearance Central Nervous System disease .</brief_summary>
	<brief_title>Cisplatin , Temozolomide , Abraxane , With Interleukin-2 Interferon Metastatic Melanoma</brief_title>
	<detailed_description>The Study Drugs : Cisplatin , nab-paclitaxel , temozolomide chemotherapy drug direct effect melanoma cell . Interferon alfa-2b IL-2 biotherapy drug stimulate immune system fight melanoma . The combination chemotherapy biotherapy drug call biochemotherapy . This first study use drug combination . Catheter : If find eligible take part study , central venous catheter ( CVC ) insert , already one . The catheter pass vein arm vein run collar bone reach wide central vein chest run heart . You receive separate consent form procedure , describes risk . Nab-paclitaxel , cisplatin , interleukin-2 give catheter . In certain situation , blood also draw catheter . Study Drug Dose Levels : You assign dose level nab-paclitaxel base join study . Up 3 dose level nab-paclitaxel test . Up 6 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose nab-paclitaxel give combination drug find . All participant receive dose level temozolomide , cisplatin , interferon alfa-2b , IL-2 . Study Drug Administration : Each study cycle last 3-5 week . The length cycle depend recovery study drug . On Day 1 cycle : - You take temozolomide mouth . - You receive nab-paclitaxel 30 minute vein 1 hour take temozolomide . - You receive cisplatin vein . Each infusion cisplatin take 45-120 minute . - You receive interferon alfa-2b injection fatty tissue . - You begin IL-2 infusion . The infusion begin receive cisplatin continue non-stop Day 5 . On Day 2 cycle : - You take temozolomide mouth . - You receive cisplatin vein 1 hour take temozolomide . - You receive interferon alfa-2b injection fatty tissue . On Day 3 cycle : - You take temozolomide mouth . - You receive cisplatin vein 1 hour take temozolomide . - You receive interferon alfa-2b injection fatty tissue . - Blood ( 4 teaspoon total ) drawn routine test test check infection blood . On Day 4 cycle : - You receive cisplatin vein . - You receive interferon alfa-2b injection fatty tissue . - Blood ( 4 teaspoon ) draw routine test . On Day 5 cycle : - You receive nab-paclitaxel vein 30 minute . - You receive interferon alfa-2b injection fatty tissue . - Blood ( 4 teaspoon ) draw routine test . Depending body reacts study drug , stay hospital 7 day . After discharged hospital , blood ( 4 teaspoon ) draw 2 time week routine test . Study Visits : Before start cycle treatment : - Your medical history record . - You physical exam . - Blood ( 1-2 tablespoon ) draw routine test check blood count . - You chest x-ray . After every 2 cycle treatment , CT scan MRI scan brain check status disease . If disease bone , PET/CT check status disease . If skin lesion , photograph check status disease . Length Study : You may receive 6 cycle study drug . You take study early disease get bad intolerable side effect occur . Follow-Up Contact : If follow-up visit doctor M. D. Anderson , call 2-4 time year learn treatment may receive . You continue receive call long possible . The phone call take 5 minute . This investigational study . Nab-paclitaxel FDA approve commercially available breast cancer . Temozolomide FDA approve commercially available brain cancer . Cisplatin FDA approve commercially available testicular , ovarian , bladder cancer . Interferon FDA approve commercially available patient melanoma surgery . IL-2 FDA approve commercially available melanoma kidney cancer . The combination drug investigational . Up 24 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Patients histologically document diagnosis advanced stage IV unresectable stage III melanoma eligible . 2 . They recurrent melanoma measurable evaluable site disease , 1.0 cm large , order ass response treatment RECIST . 3 . They expose previous chemotherapy isolation perfusion malignant melanoma previous exposure interleukin2 . Prior adjuvant interferon permitted.Prior radiation therapy metastatic melanoma permit provided patient unirradiated metastatic site response evaluation fully recover toxicity . 4 . Patients 18 year age 65 year age expect survival great 8 week Karnofsky performance status 50 % good ECOG performance status 0 , 1 2 eligible . 5 . They normal blood count WBC count equal 3000/mm^3 absolute neutrophil count equal 1500/mm^3 platelet count 100,000/mm^3 impairment renal function ( serum creatinine le 1.1 mg/dl female less 1.4 mg/dl male ) , hepatic function ( serum bilirubin level le 1.2 mg/dl ) evidence significant cardiac pulmonary dysfunction . 6 . They significant intercurrent illness active infection , uncontrolled psychiatric illness , hypercalcemia ( calcium great 11 mg ) , active GI bleeding . 1 . Patients bone metastasis . 2 . Patients brain metastasis unless disease resect corticosteroid . Patients spinal cord compression leptomeningeal disease . No major surgery radiation therapy within 21 day start treatment . 3 . Patients significant cardiac illness symptomatic coronary artery disease previous history myocardial infarction , impaired leave ventricle function ( EF less 55 % ) account organic disease hypertension valvular heart disease serious cardiac arrhythmia require therapy . Patients EKG disclose absolute QT interval great 460 msec presence serum potassium great equal 4.0 mEq/L magnesium great than/=1.8 mg/dL . 4 . Patients significant impairment pulmonary function account chronic bronchitis chronic obstructive pulmonary disease ( COPD ) result impairment vital capacity FEV1 le 75 % predict normal value . 5 . Patients symptomatic effusion account pleural , pericardial peritoneal metastasis melanoma . 6 . Patients unable stay Houston receive therapy ( first cycle ) and/or unable return followup visit require study . 7 . Patients history second malignant tumor , common skin cancer basal squamous carcinoma , within past 5 year uncertainty histological nature metastatic lesion . 8 . Patients history DVT PE exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Nab-paclitaxel</keyword>
	<keyword>Paclitaxel ( protein-bound )</keyword>
	<keyword>ABI-007</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Platinol-AQ</keyword>
	<keyword>Platinol</keyword>
	<keyword>CDDP</keyword>
	<keyword>Interleukin 2</keyword>
	<keyword>IL-2</keyword>
	<keyword>Proleukin</keyword>
	<keyword>Intron A</keyword>
	<keyword>Interferon alpha 2b</keyword>
	<keyword>Interferon alfa-2b</keyword>
	<keyword>Temodar</keyword>
	<keyword>Temozolomide</keyword>
</DOC>